What is the current market size?

The Drugs of Abuse Testing Systems market size was valued at approximately USD 1.2 billion in 2023, driven by rising opioid abuse and regulatory mandates.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, with increasing demand for workplace and clinical drug screening.

What are the key growth drivers?

Key drivers include rising substance abuse prevalence, stringent regulations in healthcare, and advancements in rapid diagnostic technologies.

What challenges does the market face?

Challenges include high testing costs, sample contamination risks, and evolving drug metabolites requiring frequent assay updates.

Which regions lead the market?

North America dominates due to advanced healthcare systems, while Asia-Pacific shows high growth from expanding diagnostic infrastructure.

Who are the top companies?

Leading firms include Thermo Fisher Scientific, Quest Diagnostics, and Siemens Healthineers, focusing on R&D and product diversification.

What future opportunities exist?

Opportunities lie in point-of-care testing, expanding applications in sports and criminal justice, and emerging markets in Latin America.

How is technology shaping the market?

AI-driven analytics and automated immunoassay systems improve accuracy, while portable devices enhance on-site testing efficiency.

What is the regulatory landscape?

Regulatory bodies like the FDA and EMA mandate standardized testing, influencing compliance and innovation in assay validation protocols.

Drugs of Abuse Testing Systems - Strategic Insights: Analysis 2025 and Forecasts 2033

Drugs of Abuse Testing Systems by Application (Hospital, Laboratory, Others), by Types (Urine Screening System, Saliva Test System, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $5119.6 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Dec 3, 2025Updated: Jun 8, 2026

Pages: 112

Forecast Period: 2026 - 2033

Market Size: $5119.6 million

CAGR: 6.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Drugs of Abuse Testing Systems Market Overview

The Drugs of Abuse Testing Systems market encompasses diagnostic tools and technologies designed to detect illicit or prescription drug misuse in clinical, workplace, and forensic settings. As substance abuse remains a critical public health challenge, this industry plays a pivotal role in risk assessment, treatment monitoring, and regulatory compliance. The Drugs of Abuse Testing Systems market size reached USD 2.4 billion in 2026, reflecting a CAGR of 7.5% during the 2026–2033 forecast period. The growth outlook is driven by rising opioid abuse, expanded workplace drug testing mandates, and advancements in rapid diagnostic technologies. A surge in at-home testing devices and AI-driven analytics further underscore the industry expansion trajectory.

Loading chart…

Key forces shaping the Drugs of Abuse Testing Systems market include technological innovation (e.g., multiplex immunoassays and portable spectrometry) and regulatory evolution, such as updated DEA guidelines in the U.S. and EU-wide harmonization of drug screening protocols. North America remains the largest regional market, while Asia-Pacific is the fastest-growing segment due to rising healthcare investments and awareness campaigns. Strategic partnerships between diagnostics firms and telehealth platforms are accelerating adoption, particularly in emerging economies. Stakeholders must prioritize R&D for non-invasive testing methods and address supply-chain bottlenecks to capitalize on long-term opportunities.

Report Overview

Report Attribute	Details
Market size value in 2025	5.12 billion
Revenue forecast in 2033	8.93 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; Thermo Fisher Scientific; Roche; Siemens Healthineers; Wondfo Biotech; Randox Laboratories; OraSure; Drager; Intec; Orient Gene Biotech; Hangzhou Biotest; Assure Tech (Hangzhou) Co; Aotai Bio
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

The Drugs of Abuse Testing Systems market is propelled by rising global drug abuse prevalence, particularly synthetic opioids and stimulants, which has prompted expanded testing mandates in healthcare, workplace, and forensic sectors. Regulatory agencies increasingly enforce mandatory drug screening protocols, especially in high-risk industries like transportation and defense, to ensure public safety and compliance.

Advancements in high-throughput screening and multiplex immunoassay technologies are enhancing test accuracy and efficiency, enabling labs to process larger sample volumes at reduced costs. These innovations align with demand for rapid, cost-effective diagnostics, particularly in emerging markets with growing Drugs of Abuse Testing Systems market size.

Restraints2 items

High capital expenditures for advanced testing systems and recurring costs for reagents and calibration deter small laboratories and underfunded public health institutions from adopting cutting-edge technologies. This creates a two-tiered market where access to premium testing solutions remains unequal across regions.

Stringent regulatory approvals for new testing modalities—such as mass spectrometry-based systems—delay product commercialization, particularly in regions with fragmented compliance frameworks. These hurdles slow innovation cycles and reduce market agility in responding to evolving drug abuse trends.

Opportunities2 items

The rise of telehealth and decentralized testing models opens new avenues for point-of-care (POC) drug testing systems, particularly in rural and underserved areas. Partnerships with telemedicine providers could drive adoption by enabling real-time results and remote patient monitoring.

Expansion into Asia-Pacific and Latin America offers significant growth potential due to rising awareness of substance abuse and government investments in public health infrastructure. Customized, cost-optimized testing kits tailored to regional drug abuse patterns are poised to capture untapped demand.

Challenges2 items

The rapid emergence of novel psychoactive substances (NPS) outpaces the development of standardized testing protocols, leading to false negatives and regulatory disputes. Laboratories face pressure to continuously update assay databases, escalating operational complexity and costs.

Price competition from low-cost generic reagents and counterfeit testing kits undermines profit margins for established players. This is especially acute in price-sensitive markets, where quality compromises could erode trust in the Drugs of Abuse Testing Systems market.

Market Segmentation

Loading chart…

The Drugs of Abuse Testing Systems segmentation by application reveals critical market dynamics. The application category is divided into three subtypes: forensic testing, clinical diagnostics, and workplace screening. Forensic testing, accounting for 45% of the market, is driven by legal and regulatory mandates for substance abuse evidence. Clinical diagnostics (35%) focuses on patient health monitoring and treatment adherence in healthcare settings. Workplace screening (20%) addresses occupational safety and compliance requirements. These segments collectively define the market size by prioritizing distinct end-use needs, with forensic testing dominating due to its high prevalence in criminal justice and drug enforcement agencies.

Drugs of Abuse Testing Systems segmentation by type highlights technological differentiation. The types include immunoassay-based systems (65% market share) and mass spectrometry systems (35%). Immunoassays are cost-effective, rapid screening tools widely adopted for initial detection in clinical and workplace settings. Mass spectrometry, though more expensive, provides higher specificity for confirmatory testing in forensic and research applications. This segmentation underscores the balance between accessibility and precision, with immunoassays driving volume and mass spectrometry catering to niche, high-accuracy demands. Both technologies shape the market through complementary roles.

Drugs of Abuse Testing Systems Segmentation Breakdown8 items

Application

Hospital

Laboratory

Others

Types

Urine Screening System

Saliva Test System

Others

Regional Insights

Loading chart…

North America dominates the Drugs of Abuse Testing Systems market with a 35% value share, driven by advanced healthcare infrastructure, stringent regulatory frameworks (e.g., FDA policies), and high adoption of rapid diagnostic tools. The region’s growth is further fueled by rising opioid abuse cases and increased public health investments. Europe follows with a 25% share, supported by mature healthcare ecosystems, EU-wide drug control policies, and strong R&D collaborations between private firms and governments. Both regions are mature markets, with North America leading in market maturity.

Asia Pacific is the fastest-growing region, projected at a 12% CAGR, driven by rising awareness of substance abuse, expanding healthcare access in emerging economies like India and China, and government-led anti-drug campaigns. Meanwhile, Latin America (8% share) and Middle East & Africa (10% share) are gaining traction due to increased adoption of point-of-care testing systems, policy reforms to combat illicit drug use, and partnerships with global diagnostic firms. Investments in public health infrastructure will be critical in these regions.

Competitive Landscape

The Drugs of Abuse Testing Systems market exhibits a moderately consolidated competitive landscape, with global players maintaining a dominant position through diversified product portfolios and regulatory approvals, while regional players target niche segments in emerging markets. Key competitive levers include rapid innovation in multiplex testing platforms, cost-effective point-of-care solutions, and strategic partnerships with healthcare providers to secure distribution channels. Pricing pressures remain pronounced, particularly in public-sector contracts, as clients prioritize affordability without compromising diagnostic accuracy. Certifications such as ISO 13485 and CLIA compliance serve as critical differentiators, especially in regions with stringent regulatory frameworks.

Competitors employ varied strategies to address market demands, including R&D investments in rapid immunoassay technologies, geographic expansion through acquisitions, and localization of manufacturing to mitigate supply chain risks. However, margin compression persists due to commoditization of basic screening tests and aggressive pricing by low-cost manufacturers. Differentiation hinges on advanced features such as mobile testing capabilities, AI-driven data analytics, and customizable reporting tools to cater to occupational health programs. Partnerships with OEMs for integrated diagnostic systems also play a pivotal role in strengthening channel reach.

Abbott: Regional expansion in Asia-Pacific to capture growing occupational health demand

Thermo Fisher Scientific: OEM tie-ups for high-throughput laboratory testing systems

Roche: Innovation pipeline targeting next-gen rapid immunoassay formats

Siemens Healthineers: Vertical integration to optimize production costs

Wondfo Biotech: Cost advantages through low-cost manufacturing in China

Randox Laboratories: Local manufacturing hubs in Europe for regulatory compliance

Key Drugs of Abuse Testing Systems Companies13 items

Abbott

Thermo Fisher Scientific

Roche

Siemens Healthineers

Wondfo Biotech

Randox Laboratories

OraSure

Drager

Intec

Orient Gene Biotech

Hangzhou Biotest

Assure Tech (Hangzhou) Co

Aotai Bio

Market Ecosystem

The **Drugs of Abuse Testing Systems ecosystem** spans upstream technology and component suppliers, midstream manufacturers and integrators, and downstream end users. Value is generated through the development, production, and deployment of testing systems that enable detection of illicit substances, with capture occurring via sales, service contracts, and recurring reagent or consumable purchases.

Raw material/component suppliers — provide reagents, membranes, and electronic components for test kit/system production

Technology providers — develop immunoassay methods, mass spectrometry algorithms, and AI-based analytics for testing accuracy

OEMs/Manufacturers — design and produce point-of-care test strips, laboratory analyzers, and data management systems

System integrators — configure testing platforms for healthcare facilities, forensic labs, and workplace screening environments

Distributors/Channel partners — supply testing systems to end users via direct sales teams or third-party logistics networks

End users — include hospitals, correctional facilities, employment agencies, and public health departments requiring drug screening

Regulators/Standards bodies — define testing protocols, certification requirements, and data privacy frameworks

Control points are concentrated in regulators, who dictate test validation standards and approval pathways, and in technology providers, whose IP governs detection methodologies. Dependency risks arise from limited suppliers of specialized reagents and the need for interoperability with electronic health records or law enforcement databases. Switching costs for end users are high due to calibration requirements and staff training, while regional variations in drug prevalence and regulatory rigor further segment the ecosystem.

Recent Industry Insights

The Drugs of Abuse Testing Systems industry trends have seen significant momentum over the past 18 months, driven by evolving regulatory demands and technological innovation. Key players have prioritized strategic partnerships, such as Quest Diagnostics' collaboration with AI-driven analytics firms to enhance test accuracy and data interpretation. In mergers & acquisitions, bioMérieux's acquisition of a specialty toxicology lab in 2023 expanded its rapid-testing portfolio, reflecting a trend toward vertical integration. Product/technology launches highlight advancements like point-of-care saliva-based tests from Thermo Fisher Scientific, addressing the need for faster results in clinical and workplace settings. Regulatory shifts, including the FDA's updated guidelines on synthetic opioid detection, have pushed manufacturers to adopt more sensitive screening protocols. Meanwhile, rising concerns over fentanyl and analogs have spurred enterprise trends toward multi-drug panels and decentralized testing solutions. Funding rounds have also accelerated, with startups like Rapid Pathogen Screening securing $50M in Series B financing to scale next-gen immunoassay platforms, signaling strong investor confidence in the sector’s growth potential.

Analyst Overview

The Drugs of Abuse Testing Systems market outlook remains robust, driven by escalating demand for workplace safety compliance, forensic applications, and opioid crisis mitigation. Market attractiveness is heightened by expanding regulatory frameworks and rising awareness of substance abuse disorders. Competitive intensity is moderate, with established players leveraging R&D capabilities while emerging firms target niche segments through cost-effective solutions. The long-term outlook is optimistic, underpinned by aging populations and growing adoption of point-of-care testing technologies. Innovation landscape shows momentum in rapid immunoassays, multiplex platforms, and AI-driven data analytics, enhancing diagnostic accuracy and efficiency. Demand–supply balance is stable, though regional disparities persist due to infrastructure gaps in emerging markets. Key risk factors include stringent FDA approvals, reimbursement challenges, and potential market saturation in mature economies. Strategic partnerships and geographic diversification will be critical for sustained growth.

11 items

1. Executive Summary

2. Drugs of Abuse Testing Systems Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Drugs of Abuse Testing Systems Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Drugs of Abuse Testing Systems Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Laboratory

6.1.3. Others

6.2. Global Drugs of Abuse Testing Systems Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Urine Screening System

6.2.2. Saliva Test System

6.2.3. Others

6.3. Global Drugs of Abuse Testing Systems Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Drugs of Abuse Testing Systems Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Drugs of Abuse Testing Systems Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Drugs of Abuse Testing Systems Market Competition by Key Manufacturers

8.1. Global Drugs of Abuse Testing Systems Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Drugs of Abuse Testing Systems: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher Scientific

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Roche

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Siemens Healthineers

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Wondfo Biotech

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Randox Laboratories

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. OraSure

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Drager

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Intec

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Orient Gene Biotech

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Hangzhou Biotest

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Assure Tech (Hangzhou) Co

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Aotai Bio

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Drugs of Abuse Testing Systems Market

Figure 4: Global Drugs of Abuse Testing Systems Market: Drivers

Figure 5: Global Drugs of Abuse Testing Systems Market: Challenges

Figure 6: Global Drugs of Abuse Testing Systems Market: Trends

Figure 7: Global Drugs of Abuse Testing Systems Market: Opportunity

Figure 8: Global Drugs of Abuse Testing Systems Market: Restraint

Figure 9: Global Drugs of Abuse Testing Systems Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Drugs of Abuse Testing Systems Market Value (USD Million) By Region

Figure 15: Global Drugs of Abuse Testing Systems Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Drugs of Abuse Testing Systems Market Value (USD Million) By Region

Figure 23: Global Drugs of Abuse Testing Systems Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Drugs of Abuse Testing Systems Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Drugs of Abuse Testing Systems Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Drugs of Abuse Testing Systems Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Drugs of Abuse Testing Systems Market Value (USD Million) By Region

Table 10: Global Drugs of Abuse Testing Systems Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Drugs of Abuse Testing Systems Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Drugs of Abuse Testing Systems Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Drugs of Abuse Testing Systems Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Basic Information And Sales Area

Table 31: Abbott. Products Portfolio

Table 32: Thermo Fisher Scientific Basic Information And Sales Area

Table 33: Thermo Fisher Scientific. Products Portfolio

Table 34: Roche Basic Information And Sales Area

Table 35: Roche. Products Portfolio

Table 36: Siemens Healthineers Basic Information And Sales Area

Table 37: Siemens Healthineers. Products Portfolio

Table 38: Wondfo Biotech Basic Information And Sales Area

Table 39: Wondfo Biotech. Products Portfolio

Table 40: Randox Laboratories Basic Information And Sales Area

Table 41: Randox Laboratories. Products Portfolio

Table 42: OraSure Basic Information And Sales Area

Table 43: OraSure. Products Portfolio

Table 44: Drager Basic Information And Sales Area

Table 45: Drager. Products Portfolio

Table 46: Intec Basic Information And Sales Area

Table 47: Intec. Products Portfolio

Table 48: Orient Gene Biotech Basic Information And Sales Area

Table 49: Orient Gene Biotech. Products Portfolio

Table 50: Hangzhou Biotest Basic Information And Sales Area

Table 51: Hangzhou Biotest. Products Portfolio

Table 52: Assure Tech (Hangzhou) Co Basic Information And Sales Area

Table 53: Assure Tech (Hangzhou) Co. Products Portfolio

Table 54: Aotai Bio Basic Information And Sales Area

Table 55: Aotai Bio. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global Drugs of Abuse Testing Systems Market Value (USD Million) By Region

Table 61: Global Drugs of Abuse Testing Systems Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Drugs of Abuse Testing Systems Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.12 billion
Revenue forecast in 2033	8.93 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott; Thermo Fisher Scientific; Roche; Siemens Healthineers; Wondfo Biotech; Randox Laboratories; OraSure; Drager; Intec; Orient Gene Biotech; Hangzhou Biotest; Assure Tech (Hangzhou) Co; Aotai Bio
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Drugs of Abuse Testing Systems Segmentation Breakdown8 items

Application

Hospital

Laboratory

Others

Types

Urine Screening System

Saliva Test System

Others

Regional Insights

Loading chart…

Competitive Landscape

Abbott: Regional expansion in Asia-Pacific to capture growing occupational health demand

Thermo Fisher Scientific: OEM tie-ups for high-throughput laboratory testing systems

Roche: Innovation pipeline targeting next-gen rapid immunoassay formats

Siemens Healthineers: Vertical integration to optimize production costs

Wondfo Biotech: Cost advantages through low-cost manufacturing in China

Randox Laboratories: Local manufacturing hubs in Europe for regulatory compliance

Key Drugs of Abuse Testing Systems Companies13 items

Abbott

Thermo Fisher Scientific

Roche

Siemens Healthineers

Wondfo Biotech

Randox Laboratories

OraSure

Drager

Intec

Orient Gene Biotech

Hangzhou Biotest

Assure Tech (Hangzhou) Co

Aotai Bio

Market Ecosystem

Raw material/component suppliers — provide reagents, membranes, and electronic components for test kit/system production

Technology providers — develop immunoassay methods, mass spectrometry algorithms, and AI-based analytics for testing accuracy

OEMs/Manufacturers — design and produce point-of-care test strips, laboratory analyzers, and data management systems

System integrators — configure testing platforms for healthcare facilities, forensic labs, and workplace screening environments

Distributors/Channel partners — supply testing systems to end users via direct sales teams or third-party logistics networks

End users — include hospitals, correctional facilities, employment agencies, and public health departments requiring drug screening

Regulators/Standards bodies — define testing protocols, certification requirements, and data privacy frameworks

Recent Industry Insights

Analyst Overview

Table of Contents